MikroBiyo is proud to be mentioned in the “Liquid Biopsy From Isolation to Downstream Applications 2018” report released by Yole Développement.
“Liquid biopsy has the potential to assist at every stage of cancer care, saving lives and cutting healthcare costs. The opportunity is huge, and the associated market is already large and growing extremely fast. According to this Yole Développement report, the liquid biopsy market will grow from $1.7B in 2017 at a CAGR2017-2023 of 29%, reaching $7.8B by 2023. This includes hardware (systems and devices) and reagent kit sales, along with service revenue, for CTC and ctDNA applications.”